SCHEMBL21597399

SCHEMBL21597399

O=C(NCC1CC1)c1c(NC(=O)C2CC2)sc2c1CC1(CC2)OCCO1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.46
KMT2A Q03164 1/20 0.45
CNR1 P21554 5/20 0.44
PTPN1 P18031 1/20 0.43
FLT3 P36888 1/20 0.42
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40
REV1 Q9UBZ9 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RORC P51449 1/20 0.38
PTGER4 P35408 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27415028 0.87 CNR2 (0.46) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21597221 0.85 CNR2 (0.52) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21603822 0.84 PTPN1 (0.61) KMT2APTPN1FLT3MAPTKDM4E
SCHEMBL21597057 0.84 CNR2 (0.50) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21597151 0.82 CNR2 (0.46) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21603795 0.80 KMT2A (0.67) CNR2KMT2ACNR1MAPTKDM4E
SCHEMBL21597053 0.80 CNR2 (0.44) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21597125 0.80 CNR2 (0.65) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21597731 0.77 CNR2 (0.50) CNR2KMT2ACNR1FLT3MAPT
SCHEMBL21597137 0.76 CNR2 (0.71) CNR2KMT2ACNR1FLT3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP claimed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO claimed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 CNR2 1326/4885KMT2A 4104/4885CNR1 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.